abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

这页面没有简体中文版本,现以English显示

文章

2007年5月1日

作者:
Abbott Laboratories

[PDF] Abbott's Commitment to Global HIV Care

In August 2006, the World Health Organization (WHO) identified heat-stable lopinavir/ritonavir (LPV/r) tablets as the recommended protease inhibitor for second-line therapy in resource-limited settings, because it is co-formulated and does not require refrigeration, which are key benefits for patients living in the developing world... To help ensure that all patients who need our HIV medicine can get it, Abbott has implemented five practical measures: - Innovation - Broad Registration - Lower-strength Tablet for Pediatric Use - Building Ongoing and Quality Supply - Tiered and Affordable Pricing.

属于以下案件的一部分

Interfaith Center on Corporate Responsibility report says Abbott Labs faces risks over access to medicines - recommends adopting human rights-based approach

Abbott Laboratories and health as a human right